RANTES release contributes to the protective action of PACAP38 against sodium nitroprusside in cortical neurons

被引:17
作者
Sanchez, Alma [1 ]
Tripathy, Debjani [1 ]
Grammas, Paula [1 ]
机构
[1] Texas Tech Univ, Hlth Sci Ctr, Garrison Inst Aging, Lubbock, TX 79430 USA
基金
美国国家卫生研究院;
关键词
PACAP; RANTES; MIP-1; alpha; Neuroprotection; Chemokine; Inflammation; Neuronal survival; CYCLASE-ACTIVATING POLYPEPTIDE; ENDOGENOUS VASOACTIVE NEUROPEPTIDES; CEREBELLAR GRANULE NEURONS; ALZHEIMERS-DISEASE; NERVOUS-SYSTEM; CHEMOKINE RECEPTORS; NEURODEGENERATIVE DISEASES; MICROGLIAL NEUROTOXICITY; INFLAMMATORY PROCESSES; PARKINSONS-DISEASE;
D O I
10.1016/j.npep.2009.05.002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Pituitary adenylate cyclase activating polypeptide (PACAP), a promising neuroprotective peptide, plays an important role during development of the nervous system and in regeneration after injury. PACAP directly promotes survival via multiple signaling systems in neurons. This neuropeptide also has immuno-modulatory properties and can regulate the expression of various inflammatory mediators such as chemokines in nonneuronal cells. Chemokines and their G protein-coupled receptors are widely distributed in the brain, suggesting important functions for these inflammatory proteins in the CNS. The ability of brain endothelial cells and glia to release chemokines has been well documented, whether neurons are also a source for these mediators is unclear. The objective of this study is to determine whether PACAP38 affects expression of regulated on activation normal T expressed and secreted (RANTES) and macrophage inflammatory protein 1-alpha (MIP-1 alpha) in cultured neurons and if these chemokines contribute to the neuroprotective effect of PACAP38. The data show that incubation of neuronal cultures with both PACAP38 and sodium nitroprusside (SNP) reduces the neuronal cell death evoked by SNP alone. PACAP38 dose-dependently increases immunodetectable levels of both RANTES and MIP-1 alpha released in the media by cultured neurons. Co-treatment with a neutralizing antibody to RANTES decreases the PACAP38-mediated protection against SNP. Although RANTES treatment of neurons increased MIP-1 alpha levels in the media and MIP-1 alpha supports neuronal survival in unstressed cultures, MIP-1 alpha does not protect neurons from SNP-induced toxicity. Furthermore, co-treatment with a MIP-1 alpha neutralizing antibody did not affect PACAP38-induced protection against SNP. These results show that the protective effect of PACAP38 on cultured neurons is mediated, in part, by release of RANTES. The ability of PACAP to directly enhance neuronal survival through multiple intracellular signaling pathways as well as via the release of neuroprotective mediators such as RANTES highlights its utility as a potential therapeutic agent for the treatment of neurodegenerative diseases. Published by Elsevier Ltd.
引用
收藏
页码:315 / 320
页数:6
相关论文
共 55 条
[1]   Neuropeptide mimetics and antagonists in the treatment of inflammatory disease: Focus on VIP and PACAP [J].
Abad, C ;
Gomariz, RP ;
Waschek, JA .
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2006, 6 (02) :151-163
[2]   Perspectives on pituitary adenylate cyclase activating polypeptide (PACAP) in the neuroendocrine, endocrine, and nervous systems [J].
Arimura, A .
JAPANESE JOURNAL OF PHYSIOLOGY, 1998, 48 (05) :301-331
[3]   Impaired nerve regeneration and enhanced neuroinflarnmatory response in mice lacking pituitary adenylyl cyclase activating peptide [J].
Armstrong, B. D. ;
Abad, C. ;
Chhith, S. ;
Cheling-Lau, G. ;
Hajji, O. E. ;
Noblita, H. ;
Waschek, J. A. .
NEUROSCIENCE, 2008, 151 (01) :63-73
[4]   CCR5+ and CXCR3+ T cells are increased in multiple sclerosis and their ligands MIP-1α and IP-10 are expressed in demyelinating brain lesions [J].
Balashov, KE ;
Rottman, JB ;
Weiner, HL ;
Hancock, WW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (12) :6873-6878
[5]   Can PACAP-38 modulate immune and endocrine responses during lipopolysaccharide (LPS)-induced acute inflammation? [J].
Baranowska-Bik, Agnieszka ;
Bik, Wojciech ;
Wolinska-Witort, Ewa ;
Chmielowska, Magdalena ;
Martynska, Lidia ;
Baranowska, Boguslawa .
VIP, PACAP, AND RELATED PEPTIDES: FROM GENE TO THERAPY, 2006, 1070 :156-160
[6]   Chemokine release is associated with the protective action of PACAP-38 against HIV envelope protein neurotoxicity [J].
Brenneman, DE ;
Hauser, JM ;
Spong, CY ;
Phillips, TM .
NEUROPEPTIDES, 2002, 36 (04) :271-280
[7]   Chemokines and pro-inflammatory cytokines in Down's syndrome: An early marker for Alzheimer-type dementia? [J].
Carta, MG ;
Serra, P ;
Ghiani, A ;
Manca, E ;
Hardoy, MC ;
Del Giacco, GS ;
Diaz, G ;
Carpiniello, B ;
Manconi, PE .
PSYCHOTHERAPY AND PSYCHOSOMATICS, 2002, 71 (04) :233-236
[8]   Chemokine receptors in the central nervous system: role in brain inflammation and neurodegenerative diseases [J].
Cartier, L ;
Hartley, O ;
Dubois-Dauphin, M ;
Krause, KH .
BRAIN RESEARCH REVIEWS, 2005, 48 (01) :16-42
[9]   PROPERTIES AND DISTRIBUTION OF RECEPTORS FOR PITUITARY ADENYLATE-CYCLASE ACTIVATING PEPTIDE (PACAP) IN RAT-BRAIN AND SPINAL-CORD [J].
CAUVIN, A ;
ROBBERECHT, P ;
DENEEF, P ;
GOURLET, P ;
VANDERMEERS, A ;
VANDERMEERSPIRET, MC ;
CHRISTOPHE, J .
REGULATORY PEPTIDES, 1991, 35 (02) :161-173
[10]   Neuroprotection by endogenous and exogenous PACAP following stroke [J].
Chen, Yun ;
Samal, Babru ;
Hamelink, Carol R. ;
Xiang, Charlie C. ;
Chen, Yong ;
Chen, Mei ;
Vaudry, David ;
Brownstein, Michael J. ;
Hallenbeck, John M. ;
Eiden, Lee E. .
REGULATORY PEPTIDES, 2006, 137 (1-2) :4-19